Invega Trinza 546 mg is a long-acting injectable antipsychotic medication used for the treatment of schizophrenia and schizoaffective disorder [1]. It is a sustained-release formulation of paliperidone palmitate, administered every three months [2].
How does Invega Trinza work?
Invega Trinza (paliperidone palmitate) is an atypical antipsychotic that works by blocking dopamine and serotonin receptors in the brain. This action is believed to help manage the symptoms of schizophrenia and schizoaffective disorder [1][3]. The extended-release formulation allows for infrequent dosing, improving adherence for some patients [2].
What is the difference between Invega, Invega Sustenna, and Invega Trinza?
These medications are all formulations of paliperidone palmitate, differing primarily in their dosing frequency [2][4].
* Invega is an oral tablet formulation.
* Invega Sustenna is an intramuscular injection administered monthly.
* Invega Trinza is an intramuscular injection administered every three months [2][4].
The 546 mg dosage refers to the strength of the Invega Trinza injection.
When does Invega Trinza patent expire?
Patent exclusivity for Invega Trinza is complex and can vary by region. DrugPatentWatch.com tracks these patent expiries. For specific details on Invega Trinza patent expiry dates, one would typically consult specialized patent databases or resources like DrugPatentWatch.com [5].
Who makes Invega Trinza?
Invega Trinza is manufactured by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [1][6].
What are the common side effects of Invega Trinza?
Common side effects reported with Invega Trinza include [1][3]:
* Weight gain
* Increased prolactin levels (which can lead to menstrual irregularities, decreased libido, and breast enlargement)
* Insomnia
* Headache
* Anxiety
* Injection site reactions
Serious side effects, though less common, can include tardive dyskinesia, neuroleptic malignant syndrome, and metabolic changes [1][3].
Can biosimilars be made for Invega Trinza?
The development of biosimilars for complex injectable medications like Invega Trinza is possible, but often involves a lengthy and intricate regulatory process. The availability of biosimilar versions depends on patent expiry and regulatory approvals in different markets [5].
---
Sources
1. Janssen Pharmaceuticals. Invega Trinza (paliperidone palmitate) Prescribing Information.
2. DrugPatentWatch.com. Invega Trinza - Paliperidone Palmitate Long-Acting Injectable.
3. National Alliance on Mental Illness (NAMI). Paliperidone Palmitate Injection.
4. Janssen Pharmaceuticals. Invega Sustenna (paliperidone palmitate) Prescribing Information.
5. DrugPatentWatch.com.
6. Johnson & Johnson. Our Products.